Key barriers to optimal management of adult asthma in Australia: Physician and patient perspectives

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1799-1807

  Heiner, Maurice McDonald ^a  

^a WESLEY HOSPITAL   (Australia)

Author keywords

Asthma; Compliance; Inhaled corticosteroids; Safety patient education

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

ADULT; AGED; ASTHMA; AUSTRALIA; CATARACT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG SAFETY; FEMALE; GLAUCOMA; HEALTH SURVEY; HOARSENESS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHARYNGITIS; PRESCRIPTION; REVIEW; SIDE EFFECT; STRUCTURED QUESTIONNAIRE; THRUSH; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; AUSTRALIA; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENTS; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34548124591     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210714     Document Type: Review

References (34)

1. Masoli M, Fabian D, Holt S, et al.; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
2. Marks GB, Correll PK, Williamson M. Asthma in Australia 2005. Med J Aust 2005;183:445-6
3. Ampon RD, Williamson M, Correll PK, et al. Impact of asthma on self-reported health status and quality of life: a population based study of Australians aged 18-64. Thorax 2005;60:735-9
4. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7
5. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7
6. Berger WE. Ciclesonide: a novel inhaled corticosteroid for the treatment of persistent asthma - a pharmacologic and clinical profile. Therapy 2005;2:167-178
7. GINA pocket guide for asthma management and prevention. Updated 2005. Available from http://www.ginasthma.com [Last accessed 18 Sep 2006]
8. Humbert M. The right tools at the right time. Chest 2006;130(Suppl):29S- 40
9. Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Corticosteroids. Chest 2004;126(Suppl):138S-49
10. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6
11. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005;116:1206-12
12. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005;99:1275-85
13. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005;60:330-7
14. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6
15. Rutherford C, Mills R, Gibson PG, et al. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003;8:371-5
16. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute 2002. Available from http://www.ginasthma.com [Last accessed 18 Sep 2006]
17. Global Asthma Physician and Patient (GAPP) Survey: global adult highlights. Available from http://www.gappsurvey.org/pdf/global-overview.pdf [Last accessed 18 Sep 2006]
18. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92
19. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-55
20. Humbert M. Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 2004;13:1349-60
21. Sawyer SM, Fardy HJ. Bridging the gap between doctors' and patients' expectations of asthma management. J Asthma 2003;40:131-8
22. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 1996;52(Suppl 6):12-9
23. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999;58(Suppl 4):25-33
24. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(Suppl):S1-40
25. Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001;86:203-10
26. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005;27:1752-63
27. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851-60
28. Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005;128:70-7
29. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003;43:365-78
30. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94:465-72
31. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther 2006;28:319-31
32. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-36
33. Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-6
34. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538-46